Ending last week, the Drug Enforcement Administration (DEA) finally reversed its project to criminalize 5 new psychedelic substances, as first reported by Microdose.
Had the agency decided to advance with the proposal, the five tryptamines (4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT) would have been moved to Schedule 1 of the Controlled Substances Act, a category reserved for substances considered to behold high potential for abuse and therefore no accepted medical use.
Public comments at the DEA’s public hearing in January and February and additional others following it seem to have enacted enough pressure on the agency, as it has withdrawn its project before the scheduled hearing in August.
A reduced group composed by therapeutic psychedelics companies, experts and attorneys are responsible for the proposal’s withdrawal and for what will most likely be the agency’s next step: a request to the HHS for a further evaluation of the five tryptamines, and a consequent reconsideration on whether or how to schedule them afterwards.
Read the lead advocates’ comments on the recent decision below.
5 psychedelic tryptamines, kept off schedule I?
— Graham Pechenik (@calyxlaw) July 22, 2022
DEA scheduling proceedings—terminated:
“DEA is withdrawing the proposed rule…canceling the public hearing & terminating the pending hearing proceedings”
Unprecedented outcome—a result of extraordinary lawyering by Matt Zorn
1/2 https://t.co/ZfBq8OJurB pic.twitter.com/OJHjhcDNil
Congratulations to challengers @TactogenInc & @MindstateDesign
— Graham Pechenik (@calyxlaw) July 22, 2022
With huge thanks also to expert statements from @AndrewChadeayne & @ProfDavidNutt
I’m grateful to serve as co-counsel w Matt, as science & common sense carry the day
Government notice: https://t.co/y79zLcaby0
2/2
Photo Courtesy of Olia Danilevich on Pexels.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.